GoodRx (NASDAQ:GDRX) Shares Down 6.4% – Should You Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price traded down 6.4% during mid-day trading on Monday . The stock traded as low as $2.19 and last traded at $2.2850. 902,947 shares were traded during mid-day trading, a decline of 69% from the average session volume of 2,952,392 shares. The stock had previously closed at $2.44.

Analyst Ratings Changes

GDRX has been the subject of a number of recent analyst reports. Morgan Stanley decreased their price objective on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. UBS Group cut their price objective on GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. Wall Street Zen lowered GoodRx from a “buy” rating to a “hold” rating in a research note on Sunday, January 25th. TD Cowen decreased their target price on GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Finally, JPMorgan Chase & Co. dropped their price target on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.73.

GoodRx Stock Performance

The firm has a market cap of $756.93 million, a P/E ratio of 24.78, a PEG ratio of 0.84 and a beta of 1.50. The stock’s 50 day moving average is $2.64 and its two-hundred day moving average is $3.44. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11.

Institutional Trading of GoodRx

Several institutional investors and hedge funds have recently made changes to their positions in GDRX. Quarry LP acquired a new position in GoodRx in the third quarter valued at about $33,000. Cetera Investment Advisers acquired a new stake in shares of GoodRx during the second quarter worth $50,000. Boothbay Fund Management LLC acquired a new stake in shares of GoodRx during the third quarter worth $43,000. Meridian Wealth Management LLC bought a new position in GoodRx during the 4th quarter worth about $29,000. Finally, Shay Capital LLC acquired a new stake in shares of GoodRx in the 3rd quarter valued at about $47,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.